Bausch+Lomb Results Presentation Deck
Total Bausch + Lomb P&L1 (Non-GAAP)²
Bausch + Lomb
Vision Care Revenue5
Surgical Revenue
Ophthalmic Pharmaceuticals Revenue 5
Total Revenue
Adj. Gross Profit²
Adj. Gross Margin²
R&D
R&D % of Revenues
Adj. SG&A²
Adj. SG&A % of Revenues³
Adj. EBITA²
Depreciation
Stock Based Compensation
Adj. EBITDA 2,3
Adj. EBITDA Margin²
Adj. Net Income Attributable to Bausch +
Lomb²
Adj EPS Attributable to Bausch + Lomb2,4
1Q23
$587M
$183M
$161 M
$931 M
$559M
60.0%
$77M
8.3%
$391M
42.0%
$91 M
$34M
$24M
$141M
15.1%
$34M
$0.10
1Q226
$560M
$174M
$155M
$889M
$541M
60.9%
$77M
8.7%
$338M
38.0%
$126M
$30M
$16M
$170M
19.1%
$85M
$0.24
Reported Change
5%
5%
4%
5%
3%
(90 bps)
0%
(16%)
(28%)
13%
50%
(17%)
(60%)
1. Products with sales outside the United States impacted by F/X changes.
2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.
3. Includes transactional FX and NCI. Currency headwind (translational and transactional) was $14M to Adj. EBITDA for Q1 2023. The Q1 FY2022 transactional FX impact was a gain of $1M.
Constant Currency
Change²
8%
9%
7%
8%
7%
(1%)
(19%)
(23%)
17%
50%
(13%)
(53%)
1Q22 results were not fully
burdened by all stand-up
costs associated with the
separation
FX Headwind in 1Q23:
Revenue: $31M
Adj. EBITDA²: $14M
●
●
4. on an basis after effect to the IPO.
BAUSCH + LOMB 5. Effective in the first quarter of 2023, certain products historically included in the reported results of the Ophthalmic Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the reported results of the Ophthalmic
Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting.
6. 1022 results were not fully burdened by all stand-up costs associated with the separation.
structure.
9View entire presentation